Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
1959
mi
from 91732
Columbus, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Hillcrest Hospital Cancer Center
2044
mi
from 91732
Mayfield Heights, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Hillcrest Hospital Cancer Center
2044
mi
from 91732
Mayfield Heights, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
1171
mi
from 91732
Oklahoma City, OK
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
1171
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Women and Infants Hospital
2563
mi
from 91732
Providence, RI
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Women and Infants Hospital
2563
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia Cancer Center
2207
mi
from 91732
Charlottesville, VA
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia Cancer Center
2207
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Augusta University Medical Center
2058
mi
from 91732
Augusta, GA
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Augusta University Medical Center
2058
mi
from 91732
Augusta, GA
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
825
mi
from 91732
Aurora, CO
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve Univ
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
2032
mi
from 91732
Cleveland, OH
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
Assessment of Tumor Resistance and Stem Cells in Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate
Assessment of Tumor Resistance and Stem Cells in Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Click here to add this to my saved trials
Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy
Yoga or Wellness Education During Breast Cancer Treatment: Establishing Community-Based Partnerships
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy
Yoga or Wellness Education During Breast Cancer Treatment: Establishing Community-Based Partnerships
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
2124
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States
Status: Enrolling
Updated:  12/31/1969
University Medical Center and UMC-North Clinic
427
mi
from 91732
Tucson, AZ
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States
Status: Enrolling
Updated: 12/31/1969
University Medical Center and UMC-North Clinic
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago
1730
mi
from 91732
Chicago, IL
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University
1791
mi
from 91732
Indianapolis, IN
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University
1791
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
2302
mi
from 91732
Baltimore, MD
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Duke University
2203
mi
from 91732
Durham, NC
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Duke University
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
1762
mi
from 91732
Nashville, TN
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
1762
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine, Lester and Sue Smith Breast Center
1357
mi
from 91732
Houston, TX
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine, Lester and Sue Smith Breast Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
326
mi
from 91732
Stockton, CA
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
326
mi
from 91732
Stockton, CA
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1182
mi
from 91732
Wichita, KA
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1182
mi
from 91732
Wichita, KA
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1218
mi
from 91732
Temple, TX
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1218
mi
from 91732
Temple, TX
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
592
mi
from 91732
Ogden, UT
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
592
mi
from 91732
Ogden, UT
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
7530
mi
from 91732
Liverpool,
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
7530
mi
from 91732
Liverpool,
Click here to add this to my saved trials
Nipple Sparing Mastectomy - Cosmetic Outcomes
Preservation of the Nipple Areolar Complex With Skin Sparing Mastectomy
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
2102
mi
from 91732
Charlotte, NC
Nipple Sparing Mastectomy - Cosmetic Outcomes
Preservation of the Nipple Areolar Complex With Skin Sparing Mastectomy
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Colorado Dept. of Anschutz Cancer (3)
825
mi
from 91732
Aurora, CO
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Colorado Dept. of Anschutz Cancer (3)
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center Onc Dept.
2435
mi
from 91732
New York, NY
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center Onc Dept.
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital Onc Dept
2375
mi
from 91732
Philadelphia, PA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital Onc Dept
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
7942
mi
from 91732
Heidelberg,
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
7942
mi
from 91732
Heidelberg,
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
5
mi
from 91732
Duarte, CA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
5
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
25
mi
from 91732
Los Angeles, CA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2486
mi
from 91732
New Haven, CT
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
2578
mi
from 91732
Boston, MA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1965
mi
from 91732
Detroit, MI
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis
2435
mi
from 91732
New York, NY
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1962
mi
from 91732
Columbus, OH
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1962
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2375
mi
from 91732
Philadelphia, PA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis
2121
mi
from 91732
Pittsburgh, PA
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1597
mi
from 91732
Memphis, TN
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1597
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1758
mi
from 91732
Nashville, TN
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1758
mi
from 91732
Nashville, TN
Click here to add this to my saved trials